| Literature DB >> 30344732 |
Songyan Han1, Weihua Yang1, Hongwei Li2.
Abstract
Application value of fiberoptic bronchoscopy combined with liquid-based cytology test (LCT) in the early diagnosis of lung cancer was investigated. Clinical data of 901 patients who had suspicious lung space-occupying lesions and underwent bronchoscopy combined with LCT in Shanxi Provincial Cancer Hospital from June 2012 to June 2016 were retrospectively analyzed. Patients were divided into four groups to receive different fiberoptic bronchoscopies combined with LCT. Patients in Group A (n=276) received bronchoscopic washing cultures (BWC), Group B (n=204) received bronchoalveolar lavage (BAL), Group C (n=187) underwent endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) and Group D (n=234) underwent transbronchial lung biopsy (TBLB). All patients received pathological biopsy to confirm the lesions. The diagnostic results of lung cancer and the incidence rates of postoperative adverse reactions/complications were analyzed and compared among the four groups. Among 901 patients, 741 cases were pathologically diagnosed with lung cancer. In Group A, there were 224 cases diagnosed with lung cancer, of which 193 cases were successfully detected with a detection rate of 86.17% and a κ-value of 0.426. In Group B, 171 cases were diagnosed with lung cancer, of which 149 cases were successfully detected with a detection rate of 87.13% and a κ-value of 0.430. In Group C, 154 cases were diagnosed with lung cancer, of which 146 cases were successfully detected with a detection rate of 94.81% and a κ-value of 0.769. In Group D, 192 cases were diagnosed with lung cancer, of which 170 cases were successfully detected with a detection rate of 88.54% and a κ-value of 0.440. Therefore, we conclude that fiberoptic bronchoscopy combined with LCT technique is safe and reliable for the diagnosis of the early-stage lung cancer.Entities:
Keywords: early-stage lung cancer; fiberoptic bronchoscopy; liquid-based cytology; pathological biopsy
Year: 2018 PMID: 30344732 PMCID: PMC6176377 DOI: 10.3892/ol.2018.9372
Source DB: PubMed Journal: Oncol Lett ISSN: 1792-1074 Impact factor: 2.967
Demographic characteristics of the patients.
| Characteristics | Total | Average age (years) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Age (years) | 20–30 | 31–40 | 41–50 | 51–60 | 61–70 | 71–80 | 81+ | ||
| Male | 15 | 21 | 113 | 207 | 169 | 53 | 1 | 579 | 57.1±10.65 |
| Female | 9 | 20 | 66 | 121 | 80 | 24 | 2 | 322 | 55.2±11.35 |
| Total | 24 | 41 | 179 | 328 | 249 | 77 | 3 | 901 | 56.2±11.02 |
A total of 901 patients receiving fiberoptic bronchoscopy were selected in this study, including 579 males and 322 females.
Comparison of baseline data among the four groups [n (%)].
| Items | Group A (n=276) | Group B (n=204) | Group C (n=187) | Group D (n=234) | t | Ρ-value |
|---|---|---|---|---|---|---|
| Sex | 0.930 | 0.818 | ||||
| Male | 180 (65.22) | 125 (61.27) | 125 (66.84) | 149 (63.68) | ||
| Female | 96 (34.78) | 79 (38.73) | 62 (33.16) | 85 (36.32) | ||
| Age (years) | 7.676 | 0.053 | ||||
| <58 | 121 (43.84) | 115 (56.38) | 90 (48.13) | 110 (47.01) | ||
| ≥58 | 155 (56.16) | 89 (43.63) | 97 (51.87) | 124 (52.99) | ||
| Smoking | 0.295 | 0.961 | ||||
| Yes | 98 (35.51) | 68 (33.33) | 63 (33.69) | 80 (34.19) | ||
| No | 178 (64.49) | 136 (66.67) | 124 (66.31) | 154 (65.81) |
Results of fiberoptic bronchoscopy combined with LCT and pathology as well as conformity (n, κ).
| Pathological tissue | ||||
|---|---|---|---|---|
| LCT | Positive | Negative | Total | κ-value |
| Group A (BWC) | ||||
| Positive | 193 | 21 | 214 | 0.426 |
| Negative | 31 | 31 | 62 | |
| Subtotal | 224 | 52 | 276 | |
| Group B (BAL) | ||||
| Positive | 149 | 13 | 162 | 0.430 |
| Negative | 22 | 20 | 42 | |
| Subtotal | 171 | 33 | 204 | |
| Group C (EBUS-TBNA) | ||||
| Positive | 146 | 5 | 151 | 0.769 |
| Negative | 8 | 28 | 36 | |
| Subtotal | 154 | 33 | 187 | |
| Group D (TBLB) | ||||
| Positive | 170 | 18 | 188 | 0.440 |
| Negative | 22 | 24 | 46 | |
| Subtotal | 192 | 42 | 234 | |
| Total | 741 | 160 | 901 | |
LCT, liquid-based cytology test; BWC, bronchoscopic washing cultures; BAL, bronchoalveolar lavage; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; TBLB, transbronchial lung biopsy.
Comparison of the detection rate of fiberoptic bronchoscopy combined with LCT among the four groups (%).
| Fiberoptic bronchoscopy combined with LCT | Sensitivity[ | Specificity | Positive predictive value | Negative predictive value | False positive rate | False negative rate |
|---|---|---|---|---|---|---|
| Group A (BWC) | 86.17% (193/224) | 59.62% (31/52) | 90.19% (193/214) | 50.00% (31/62) | 40.38% (21/52) | 13.84% (31/224) |
| Group B (BAL) | 87.13% (149/171) | 60.61% (20/33) | 91.98% (149/162) | 47.62% (20/42) | 39.39% (13/33) | 12.87% (22/171) |
| Group C (EBUS-TBNA) | 94.81% (146/154) | 84.85% (28/33) | 96.69% (146/151) | 77.78% (28/36) | 15.15% (5/33) | 5.19% (8/154) |
| Group D (TBLB) | 88.54% (170/192) | 57.14 (24/42) | 90.43% (170/188) | 52.17% (24/46) | 42.86% (18/42) | 11.46% (22/192) |
| χ2 | 7.642 | 7.707 | 6.118 | 8.094 | 6.634 | 7.642 |
| P-value | 0.054 | 0.052 | 0.106 | 0.044 | 0.085 | 0.054 |
Detected sensitivity/detection rate = the number of cases successfully diagnosed with lung cancer through pathology by fiberoptic bronchoscopy combined with LCT within the group/the number of cases pathologically diagnosed with lung cancer within the group ×100%. LCT, liquid-based cytology test; BWC, bronchoscopic washing cultures; BAL, bronchoalveolar lavage; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; TBLB, transbronchial lung biopsy.
Comparison of false negative rate among the four groups.
| Control group | χ2 | P-value |
|---|---|---|
| A (BWC) | ||
| B (BAL) | 0.079 | 0.778 |
| C (EBUS-TBNA) | 7.370 | 0.007 |
| D (TBLB) | 0.527 | 0.468 |
| B (BAL) | ||
| C (EBUS-TBNA) | 5.690 | 0.017 |
| D (TBLB) | 0.168 | 0.682 |
| C (EBUS-TBNA) | ||
| D (TBLB) | 4.234 | 0.040 |
BWC, bronchoscopic washing cultures; BAL, bronchoalveolar lavage; EBUS-TBNA, endobronchial ultrasound-guided transbronchial needle aspiration; TBLB, transbronchial lung biopsy.
Comparison of the incidence rates of complications/adverse reactions among the four groups.
| Group | Hemorrhage/hemoptysis | Hemothorax | Pneumothorax | Lung infection | Tracheal injury/spasm | Hyoxemia | Arrhythmia/heart failure | Total n (%) |
|---|---|---|---|---|---|---|---|---|
| Group A (n=276) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.36) |
| Group B (n=204) | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 (0.49) |
| Group C (n=187) | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 (0.53) |
| Group D (n=234) | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 (0.85) |
| χ2 | 2.046 | 5.741 | 3.618 | 0.583 | ||||
| P-value | 0.563 | 0.126 | 0.306 | 0.900 |